CA
VNDA icon

Cliff Asness’s Vanda Pharmaceuticals VNDA Stock Holding History

Cliff Asness’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.4M Buy
3,497,695
+1,894,119
+118% +$12.4M 0.01% 1152
2026
Q1 		$11.1M Buy
1,603,576
+976,570
+156% +$7.53M 0.01% 1292
2025
Q4 		$5.53M Sell
627,006
-41,460
-6% -$228K ﹤0.01% 1521
2025
Q3 		$3.34M Buy
668,466
+532,742
+393% +$2.47M ﹤0.01% 1682
2025
Q2 		$641K Buy
135,724
+84,164
+163% +$368K ﹤0.01% 2469
2025
Q1 		$237K Buy
51,560
+1,581
+3% +$7.37K ﹤0.01% 2800
2024
Q4 		$239K Sell
49,979
-15,944
-24% -$76.6K ﹤0.01% 2601
2024
Q3 		$309K Sell
65,923
-9,966
-13% -$53.4K ﹤0.01% 2382
2024
Q2 		$429K Buy
75,889
+48,945
+182% +$253K ﹤0.01% 2119
2024
Q1 		$111K Buy
26,944
+10,699
+66% +$42.8K ﹤0.01% 2329
2023
Q4 		$68.6K Buy
+16,245
New +$65.5K ﹤0.01% 2295
2019
Q3 		– Sell
-17,911
Closed -$252K – 2170
2019
Q2 		$252K Hold
17,911
– – ﹤0.01% 1925
2019
Q1 		$330K Buy
17,911
+3,916
+28% +$89.2K ﹤0.01% 1938
2018
Q4 		$366K Buy
+13,995
New +$329K ﹤0.01% 1893
2018
Q1 		– Sell
-11,896
Closed -$181K – 2281
2017
Q4 		$181K Hold
11,896
– – ﹤0.01% 2166
2017
Q3 		$213K Sell
11,896
-13,477
-53% -$226K ﹤0.01% 2157
2017
Q2 		$414K Hold
25,373
– – ﹤0.01% 1957
2017
Q1 		$355K Buy
25,373
+11,400
+82% +$162K ﹤0.01% 1977
2016
Q4 		$223K Buy
+13,973
New +$225K ﹤0.01% 2131
2015
Q1 		– Sell
-12,413
Closed -$178K – 2321
2014
Q4 		$178K Sell
12,413
-31,900
-72% -$377K ﹤0.01% 2385
2014
Q3 		$460K Hold
44,313
– – ﹤0.01% 1973
2014
Q2 		$717K Sell
44,313
-30,200
-41% -$402K ﹤0.01% 1813
2014
Q1 		$1.21M Hold
74,513
– – ﹤0.01% 1602
2013
Q4 		$925K Buy
74,513
+39,413
+112% +$396K ﹤0.01% 1773
2013
Q3 		$385K Buy
35,100
+20,200
+136% +$216K ﹤0.01% 2107
2013
Q2 		$120K Buy
+14,900
New +$100K ﹤0.01% 2272

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cliff Asness's VNDA Position: Q2 2026 in Review

Cliff Asness increased its Vanda Pharmaceuticals (VNDA) stake by 118% in Q2 2026, buying an estimated $12.4M and bringing the position to 3,497,695 shares worth $21.4M. The position accounts for 0.01% of the portfolio, ranked #1152.

Cliff Asness first reported a position in VNDA in Q2 2013 and has held it in 26 quarters since. 171 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Cliff Asness held 3,497,695 shares of Vanda Pharmaceuticals worth $21.4M as of Q2 2026.
  • Cliff Asness bought 1,894,119 Vanda Pharmaceuticals shares in Q2 2026, an estimated $12.4M.
  • Vanda Pharmaceuticals made up 0.01% of Cliff Asness's portfolio in Q2 2026, its #1152 holding.
  • Cliff Asness first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 26 quarters since.
  • 171 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.